What Are Biomarkers and Why Do We Need Them?

Biomarkers are measurable characteristics that provide information about what is happening inside the body. They may indicate a normal biological process, the presence or progression of a disease, or the body’s response to a treatment or environmental exposure. Blood glucose, cholesterol, blood pressure, gene mutations, protein concentrations, and tumor size are all familiar examples of biomarkers. Some biological markers help identify disease, while others estimate future risk, predict treatment response, monitor disease progression, or reveal possible treatment-related toxicity.

Biomarkers are important because symptoms alone do not always provide a complete picture of a person’s health. A disease may begin changing cells, proteins, genes, or tissues long before noticeable symptoms develop. By making these changes measurable, biomarkers can support earlier investigation, more precise disease diagnosis, informed treatment decisions, and more effective medical research.

What Is a Biomarker?

A biomarker, also called a biological marker, is a defined characteristic that can be objectively measured as an indicator of:

• A normal biological process
• A disease-related or pathogenic process
• A response to an exposure
• A response to a medical intervention

Biomarkers can be molecules found in biological samples, but the term is much broader than blood-test results. A biological marker may be a protein, gene variant, metabolite, cell population, tissue feature, imaging result, or physiological Measurement.

For example:

• Blood glucose reflects glucose regulation.
• Blood pressure provides information about cardiovascular function.
• Troponin may indicate injury to the heart muscle.
• A gene mutation may help identify a molecular disease subtype.
• Tumor size on an imaging scan may help assess disease burden.
• A cytokine concentration may provide information about immune activity.

A biomarker is therefore not one specific substance or test. It is a measurable characteristic used to answer a defined biological, medical, or research question.

How Do Biomarkers Work?

Normal and abnormal biological processes can change the composition or behavior of cells, tissues, and body fluids. These changes may alter gene expression, protein concentration, enzyme activity, immune-cell populations, metabolism, or organ function.

Researchers and healthcare professionals use laboratory tests, medical imaging, and physiological measurements to detect these signals. The results are then interpreted in relation to a reference range, threshold, previous result, or comparison group.

A biomarker study generally involves four connected elements:

1. A biological characteristic of interest
2. A sample or measurement source
3. A reliable method for measuring the characteristic
4. A clearly defined purpose for interpreting the result

The intended purpose is especially important. An elevated protein concentration might support disease diagnosis in one setting, monitor disease progression in another, or assess treatment response in a clinical study. The meaning of a biomarker depends not only on what is measured but also on why, when, how, and in whom it is measured.

Why Do We Need Biomarkers?

Biomarkers translate complex biological changes into measurable information. This information can improve research, support medical decisions, and help scientists understand how diseases begin and progress.

Supporting disease diagnosis

Biomarkers for disease diagnosis help detect or confirm the presence of a condition. They may also distinguish between diseases that produce similar symptoms or identify different molecular forms of the same disease. For example, a person may have symptoms that several conditions could cause. A laboratory result, imaging feature, or molecular marker can provide additional evidence that helps narrow the possible Diagnosis.

Biomarkers rarely operate in isolation. A responsible diagnosis usually considers biomarker results alongside symptoms, medical history, physical findings, imaging, and other test results.

Enabling earlier detection

Early detection can create opportunities for earlier investigation and intervention. Certain biomarkers may reveal biological changes before a disease produces severe or obvious symptoms. This does not mean that every new biomarker is automatically suitable for early detection. A marker must be carefully evaluated to determine whether it can distinguish early disease from normal variation or unrelated conditions.

When supported by strong evidence, early-detection biomarkers may help identify:

• Initial cellular abnormalities
• Low levels of disease-associated proteins
• Early organ injury
• Molecular changes linked to disease development
• Recurrence before more obvious clinical changes appear

The value of early detection depends on the accuracy of the test and whether acting on the result can produce a meaningful benefit.

Estimating disease risk

Some biomarkers indicate that a person may have an increased likelihood of developing a disease in the future. Examples include inherited genetic variants, metabolic measurements, and cardiovascular risk markers. A risk biomarker does not guarantee that the disease will occur. It adds one piece of information to a broader assessment that may also include age, lifestyle, environmental exposures, family history, and existing medical conditions.

Predicting disease outcomes

Prognostic biomarkers provide information about the likely course of an existing disease. They may help estimate the possibility of progression, recurrence, complications, or another clinical event. This information can support patient stratification in research and help identify groups that may require closer monitoring.

Selecting suitable treatments

People with the same general Diagnosis may have meaningful molecular differences. A treatment that works well for one subgroup may have little benefit for another. Predictive biomarkers can help identify individuals who are more likely to experience a favorable or unfavorable response to a specific intervention. This is a central principle of precision medicine, in which treatment decisions are increasingly guided by biological characteristics rather than a disease label alone.

Monitoring disease progression

Biomarkers for monitoring disease progression are measured repeatedly over time. Researchers and healthcare teams can compare results to determine whether a condition is stable, improving, or becoming more severe.

Monitoring biomarkers may help answer questions such as:

• Is the disease progressing?
• Has the severity changed?
• Is a new abnormality developing?
• Is the condition responding to treatment?
• Has the disease returned after treatment?
• Does the treatment plan require further evaluation?

Repeated measurements are often more informative than a single result because they show the direction and rate of biological change.

Measuring treatment response

Response biomarkers provide evidence that the body has reacted to an intervention. They can show whether a drug engages its intended target, affects a biological pathway, or produces the expected physiological change. These markers are valuable in drug development because they can provide early evidence of biological activity, support dose selection, and help researchers understand why an experimental treatment succeeds or fails.

Evaluating safety

Safety biomarkers indicate the presence or likelihood of toxicity or another harmful effect. Changes in liver, kidney, cardiac, or hematological markers may be evaluated during preclinical studies, clinical trials, and treatment monitoring. Reliable safety information can help researchers identify adverse biological effects, compare doses, and make better-informed development decisions.

What Are the Seven Main Types of Biomarkers?

The FDA–NIH BEST framework organizes biomarkers into seven categories according to their intended use.

1. Susceptibility or risk biomarkers

A susceptibility or risk biomarker indicates the possibility that a person who does not currently have a disease may develop it in the future.Examples may include inherited genetic variants or biological measurements associated with increased disease risk. These biomarkers provide probability-based information rather than certainty.

2. Diagnostic biomarkers

Diagnostic biomarkers detect or confirm the presence of a disease or condition. They may also help classify a particular disease subtype. Examples include pathogen-associated genetic material, disease-related protein expression, and molecular features used to characterize certain tumors.

3. Monitoring biomarkers

Monitoring biomarkers is measured repeatedly to evaluate the status of a disease, medical condition, exposure, or intervention. Examples include viral load during antiviral treatment, hemoglobin A1c in diabetes management, or tumor burden during cancer therapy.

4. Prognostic biomarkers

A prognostic biomarker indicates the likelihood of a future clinical event, disease recurrence, or disease progression in a person who already has the condition. It describes the probable course of the disease rather than the likely effect of one specific treatment.

5. Predictive biomarkers

Predictive biomarkers identify individuals who are more likely to experience a favorable or unfavorable response to a particular treatment or exposure. They may guide treatment selection and help researchers enroll appropriate participants in clinical trials.

6. Pharmacodynamic or response biomarkers

A pharmacodynamic or response biomarker shows that a biological response has occurred after an intervention. It may demonstrate target engagement, pathway inhibition, immune activation, or another measurable biological effect.

7. Safety biomarkers

Safety biomarkers indicate the presence or potential risk of toxicity. They can help reveal harmful effects on organs, tissues, blood cells, or other biological systems.

Types of Biomarkers Based on What Is Measured

Molecular biomarkers

Molecular biomarkers include measurable proteins, nucleic acids, lipids, carbohydrates, hormones, enzymes, and metabolites. They may be detected in blood, urine, saliva, tissue, cerebrospinal fluid, or other biological materials.

Protein biomarkers

Proteins are among the most widely studied disease biomarkers because they often reflect active biological processes.

Changes in protein concentration, structure, localization, modification, or activity may provide information about:

• Inflammation
• Immune activity
• Tissue damage
• Infection
• Tumor biology
• Cell signaling
• Treatment response

Protein biomarkers may be measured using ELISA, Western blotting, immunohistochemistry, flow cytometry, mass spectrometry, and other analytical methods.

Genetic and genomic biomarkers

Genetic biomarkers include inherited variants, acquired mutations, gene-copy changes, and other DNA characteristics. Genomic markers can help identify inherited risk, classify disease, or predict sensitivity to certain treatments.

RNA biomarkers

Messenger RNA, microRNA, and other RNA molecules can reflect patterns of gene activity. Researchers study RNA biomarkers to understand biological pathways, disease subtypes, and treatment-related changes.

Metabolic biomarkers

Metabolites are small molecules produced or altered by biological processes. Their concentrations can provide information about metabolism, organ function, environmental exposure, nutrition, or disease.

Cellular biomarkers

A cellular biomarker may be a specific cell population, cell-surface marker, morphological feature, or activation state.Examples include immune-cell counts, circulating tumor cells, and changes in cell-surface protein expression.

Histologic biomarkers

Histologic biomarkers are characteristics detected in tissue. They may include cell architecture, protein expression, tumor grade, or the presence of particular immune-cell populations.

Imaging biomarkers

Imaging biomarkers are objectively measured characteristics obtained through techniques such as magnetic resonance imaging, computed tomography, positron emission tomography, ultrasound, or optical imaging. They can provide information about structure, function, blood flow, metabolism, or disease burden.

Physiological biomarkers

Physiological biomarkers include measurements such as blood pressure, heart rate, body temperature, respiratory rate, and lung capacity.

Common Examples of Biomarkers

How Are Biomarkers Measured?

Different analytical methods are suited to different biomarker forms.

ELISA

An enzyme-linked immunosorbent assay uses antibodies to detect and quantify proteins, antibodies, hormones, cytokines, and other targets. It is widely used because it can offer sensitive and scalable measurements.

Western blotting

Western blotting separates proteins according to size before antibody-based detection. It can help confirm protein expression and provide information about the approximate molecular weight.

Immunohistochemistry

Immunohistochemistry uses antibodies to detect proteins in tissue sections. It shows both the presence and location of a target within the tissue.

Flow cytometry

Flow cytometry evaluates physical and molecular characteristics of individual cells. It is especially valuable for analyzing cell populations and surface markers.

PCR and quantitative PCR

Polymerase chain reaction methods detect and quantify selected DNA or RNA sequences. They are commonly used in genetic, infectious-disease, and gene-expression research.

Next-generation sequencing

Sequencing technologies can examine many DNA or RNA targets simultaneously. They support broad molecular profiling and the discovery of new biomarkers.

Mass spectrometry

Mass spectrometry can identify and quantify proteins, peptides, lipids, metabolites, and other molecules. It is a powerful tool for biomarker discovery and characterization.

Medical imaging

Imaging methods provide structural or functional measurements without directly analyzing a fluid or tissue specimen.

How Are New Biomarkers Discovered?

New biomarkers are often identified by comparing samples or data from different study groups.

Researchers may compare:

• People with and without a disease
• Early- and late-stage disease
• Responders and nonresponders to treatment
• Individuals with and without treatment toxicity
• Samples collected before and after an intervention

Discovery approaches may use genomics, transcriptomics, proteomics, metabolomics, imaging, immunoassays, sequencing, mass spectrometry, or computational analysis.

A typical discovery process includes:

1. Defining the biological or medical question
2. Selecting appropriate study groups and samples
3. Measuring a large set of candidate characteristics
4. Identifying meaningful differences
5. Replicating the findings in independent samples
6. Developing a practical assay
7. Evaluating analytical and clinical performance

A discovery is an encouraging beginning, not proof that a candidate is ready for routine use.

What Makes a Good Biomarker?

A good biomarker must be appropriate for its intended purpose. No characteristic is automatically useful in every disease, population, or testing environment.

An effective biomarker should ideally be:

Biologically relevant

It should have a credible relationship with the process or condition being investigated.

Accurately measurable

The analytical method should measure the intended target correctly.

Precise and reproducible

Repeated measurements should produce consistent results under defined conditions and, where necessary, across laboratories.

Sufficiently sensitive

The test should detect the target or biological state at the level required for its intended use.

Sufficiently specific

The marker should distinguish the target condition from relevant alternatives without producing excessive false-positive findings.

Stable

The biomarker should remain sufficiently stable during collection, processing, transport, and storage.

Accessible

The required sample and measurement procedure should be practical for the research or medical setting.

Interpretable

Researchers need appropriate reference values, thresholds, or comparison methods.

Actionable

The result should contribute meaningful information to a research or medical decision.

Validated for a defined context

The biomarker must be evaluated in the population, sample type, assay, and application for which it will be used.

Biomarker Discovery Is Not the Same as Biomarker Validation

Many potential markers show promising results in an initial experiment but fail to perform consistently in larger or independent studies. Validation determines whether the biomarker and its measurement method are dependable enough for the proposed purpose.

Analytical validation

Analytical validation evaluates how reliably an assay measures the biomarker.

Important performance characteristics may include:

• Accuracy
• Precision
• Analytical sensitivity
• Analytical specificity
• Limit of detection
• Limit of quantification
• Reproducibility
• Linearity
• Sample stability
• Assay interference
• Calibration
• Lot-to-lot consistency

Clinical validation

Clinical validation evaluates whether the biomarker is meaningfully associated with the disease, outcome, biological state, or response it is intended to represent.

Clinical utility

Clinical utility asks whether using the biomarker leads to a useful decision or improved outcome. A marker may be technically measurable and statistically associated with disease without providing enough practical value to guide care.

Biomarkers for Disease Diagnosis

Biomarkers for disease diagnosis can help detect, confirm, or classify a condition. Their usefulness depends on sensitivity, specificity, prevalence, threshold selection, and the consequences of false results. A sensitive marker can identify a high proportion of people who have the condition. A specific marker can correctly exclude many people who do not have it.

Neither Measurement should be considered alone. A highly sensitive test may produce unnecessary false-positive findings, while a highly specific test may miss some cases if its sensitivity is inadequate. Strong diagnostic strategies often combine multiple forms of information, such as:

• Symptoms and medical history
• Physical examination
• Laboratory biomarkers
• Imaging findings
• Molecular tests
• Repeated measurements

The best biomarkers for disease diagnosis provide reliable information that complements the broader clinical or research assessment.

Biomarkers for Monitoring Disease Progression

A monitoring biomarker is assessed repeatedly over time. Its value comes from revealing change rather than providing only a single measurement.

Biomarkers for monitoring disease progression may indicate:

• Worsening disease severity
• Development of new abnormalities
• Stabilization of the condition
• Favorable treatment response
• Unfavorable treatment response
• Recurrence after treatment

Monitoring requires consistency. Changes in sample collection, storage, assay platform, calibration, or laboratory procedure can make results difficult to compare. Reliable longitudinal monitoring, therefore, depends on standardized methods and appropriate quality controls.

Biomarkers in Drug Discovery and Development

Biomarkers can contribute throughout the development of a new therapy.

Target identification

Disease-associated genes, proteins, receptors, and pathways may reveal potential therapeutic targets.

Preclinical studies

Researchers can use biomarkers to evaluate target engagement, biological activity, and toxicity in model systems.

Clinical-trial enrollment

Diagnostic, susceptibility, prognostic, or predictive markers can help define suitable study populations.

Dose selection

Response and safety biomarkers can provide evidence about biological activity and tolerability at different doses.

Proof of mechanism

A change in a pathway-associated marker may show that an experimental treatment is affecting its intended biological mechanism.

Treatment-response assessment

Repeated measurements can reveal whether biological activity changes during treatment.

Safety monitoring

Biomarkers can identify potential organ injury or another adverse response during development.

A biomarker used in drug development should have a clearly stated context of use. This context describes its functional category and the specific purpose for which it is intended.

Biomarkers and Precision Medicine

Traditional disease categories can include people whose conditions have different molecular causes. Biomarkers make it possible to divide these broad groups into more biologically meaningful subgroups.

They may help determine:

• Which disease subtype is present
• Whether a treatment target is expressed
• Who may benefit from a particular therapy
• Who may face an increased risk of toxicity
• Whether resistance is developing
• Whether the disease is responding

This approach creates valuable opportunities for more focused research and better-informed treatment strategies.

Biomarkers, Symptoms, and Clinical Endpoints

A symptom is experienced and reported by a person. A biomarker is objectively measured.

For example:

• Fatigue is a symptom; hemoglobin concentration is a biomarker.
• Pain is a symptom; an inflammatory protein concentration may be a biomarker.
• Shortness of breath is a symptom; oxygen saturation is a biomarker.

A clinical endpoint describes how a person feels, functions, or survives. Examples include pain reduction, improved mobility, occurrence of stroke, and survival. Biomarkers can provide valuable biological information, but they are not automatically substitutes for meaningful clinical outcomes.

Is Every Biomarker a Surrogate Endpoint?

No. A surrogate endpoint is a biomarker or intermediate endpoint intended to substitute for a clinical endpoint. A biomarker may show that a treatment affects a biological pathway without proving that the treatment helps people live longer, feel better, or function more effectively.

Strong evidence is required before a biomarker can reliably serve as a substitute for a clinical outcome. Therefore, not every biological marker should be described as a validated surrogate endpoint.

How Research Reagents Support Biomarker Studies

Reliable biomarker research depends on well-characterized assays and research materials. Recombinant proteins can serve as assay-development targets, reference materials, immunogens, or positive controls. Antibodies support the detection and Measurement of protein biomarkers, while cytokines, viral antigens, enzymes, and ELISA kits can contribute to research across immunology, infection, oncology, and other fields.

Beta LifeScience provides recombinant proteins, antibodies, cytokines, viral antigens, enzymes, ELISA kits, and custom protein services for a range of life-science research applications. Researchers should select reagents according to the intended assay, required sensitivity, sample type, target concentration, specificity, and research context.

The Future of Biomarker Research

Advances in technology are expanding both the number and complexity of measurable biological signals.

Promising research areas include:

• Multi-omics analysis
• Liquid biopsy
• Single-cell analysis
• Spatial biology
• High-sensitivity protein detection
• Digital biomarkers
• Continuous physiological monitoring
• Artificial intelligence-assisted data analysis

Combining genomic, protein, metabolic, cellular, imaging, and clinical information may provide a more complete view than relying on a single marker. The goal is not simply to generate more measurements. It is to identify reliable and interpretable biomarkers that answer important questions and support meaningful decisions.

FAQs

What is a biomarker in simple words?

A biomarker is a measurable sign that provides information about a biological process, disease, or response to a treatment or exposure.

What are biological markers?

Biological markers are measurable characteristics such as proteins, genes, metabolites, cells, imaging features, or physiological measurements. The terms “biological markers” and “biomarkers” are generally used interchangeably.

Why are biomarkers important?

They can support early detection, disease diagnosis, risk assessment, treatment selection, monitoring of disease progression, safety evaluation, and drug development.

What are examples of disease biomarkers?

Examples include blood glucose, C-reactive protein, troponin, creatinine, viral nucleic acids, tumor-associated gene mutations, and disease-related protein expression.

Are biomarkers only found in blood?

No. They can be detected in blood, urine, saliva, cerebrospinal fluid, tissue, cells, stool, breath, medical images, and physiological signals.

Can proteins be biomarkers?

Yes. Proteins are widely studied because their concentration, activity, structure, modification, or location can reflect active biological and disease processes.

Conclusion

Biomarkers give researchers and healthcare professionals measurable insight into health, disease, and treatment response. They can support disease diagnosis, enable earlier investigation, estimate risk and prognosis, guide treatment selection, monitor disease progression, and improve drug development. However, the value of a biomarker depends on more than its association with a disease. A useful marker must be measured by a reliable assay, validated in an appropriate population, and interpreted within a clearly defined context.

As discovery technologies and analytical methods continue to advance, new biomarkers can create positive opportunities for more precise research, better disease understanding, and increasingly informed medical innovation. The greatest progress will come not from measuring everything possible, but from identifying biological markers that are reliable, meaningful, and genuinely useful.